The Cumulative Effect of Antipsychotic Usage on Mortality in Schizophrenia: A Nationwide Population-based Cohort Study in Korea

Gyurin Kim¹, Soo Jung Rim¹, Minkyung Jo¹, Min Geu Lee¹, Se Jin Park¹, Subin Park²

¹Department of Research Planning, ²Mental Health Research Institute, National Center for Mental Health, Seoul, Korea

**Objective:** To investigate the cumulative effect of antipsychotics at different dosages on mortality in patients with schizophrenia.

**Methods:** We analyzed data from the Korean National Health Insurance System—National Sample Cohort covering the 2002–2013 period. We used Cox regression analysis to calculate hazard ratios for mortality risks according to cumulative antipsychotic exposure levels (low, moderate, and high).

**Results:** Our analyses revealed no significant association between antipsychotic exposure and mortality (either all-cause or cause-specific) in patients with schizophrenia.

**Conclusion:** Our results imply that the excess mortality of patients with schizophrenia is attributable to factors other than antipsychotic usage.

**KEY WORDS:** Schizophrenia; Antipsychotics; Mortality; South Korea.

**INTRODUCTION**

Schizophrenia is a mental disorder that features symptoms such as delusions, hallucinations, and disorganized speech and behavior, and it causes multifaceted dysfunction in life [1]. The median lifetime prevalence rate of schizophrenia is reported as 0.48% (interquartile range, 0.34–0.85%) [2]. In spite of the low prevalence rate, the burden that schizophrenia places on patients, family members, and society is tremendous [3]. According to the Global Burden of Disease Study 2017, there were 1.13 million incident cases of schizophrenia and 12.66 million (95% uncertainty interval, 9.48–15.56 million) disability-adjusted life years due to schizophrenia in 2017 [4].

One of the major burdens of schizophrenia is premature mortality [5]. Patients with schizophrenia have a higher risk of all-cause mortality and mortality due to specific causes (e.g., cardiovascular disease, neoplasm, and suicide) when compared with the general population [6,7]. This premature mortality has generally been attributed to factors such as unhealthy lifestyles, alcohol and substance abuse, and comorbid somatic diseases [6,8].

Another factor potentially related to mortality in patients with schizophrenia is their antipsychotic usage, but the literature contains mixed results. A systematic review suggested that long-term usage of antipsychotics may increase mortality [9], but other studies have found that exposure (any, current, or cumulative) to antipsychotics reduces mortality risks [10–15]. Moreover, a recent study from Sweden [16] found that exposure to antipsychotics exhibited a U-shaped association with all-cause mortality, with the no-usage group having the highest overall mortality rate followed by the high-exposure group. The authors suggested that adequate antipsychotic dosages (low or moderate) lower mortality risks for patients with schizophrenia and that excess mortality of patients with schizophrenia is due to other factors, not antipsychotic usage [16].

However, studies on the effect of antipsychotics on
mortality in patients with schizophrenia are scarce, and studies on the cumulative dose-specific effects of anti-psychotics on mortality are rare. It is thus difficult to draw firm conclusions on the cumulative dose-specific effects of antipsychotics on mortality. We therefore conducted a nationwide population-based cohort study to investigate the cumulative dose-specific effects of antipsychotics on all-cause and cause-specific mortality in patients with schizophrenia in the Republic of Korea.

METHODS

We conducted this study with data from the Korean National Health Insurance System-National Sample Cohort (NHIS-NSC) provided by the Korean National Health Insurance Corporation. The Korean NHIS system, which was established for claims reimbursement purposes, includes the entire national population (approximately 50 million people). For representative sampling of the NHIS data, 756 strata based on 18 groups for age, 21 groups for income level by insurance type, and two groups for sex were set up with data from 2002. The NHIS-NSC data sample includes 1,025,340 individuals, which is equivalent to 2.2% of all NHIS members in 2002.

For the present study, we selected individuals from the NHIS-NSC dataset who had at least one primary diagnosis (outpatient or inpatient) for the International Classification of Diseases, 10th Revision (ICD-10) codes of F20 to F25, which correspond to schizophrenia and related diagnoses. In total, 9,978 individuals were included in the present study. We followed these individuals from their initial diagnosis dates until death or December 31, 2013, whichever came first. Whether the patients were still alive on December 31, 2013, was determined by linkage to the database of the Statistics Korea and the specific cause of mortality was recorded based on the ICD-10 codes. The outcomes of interest were all-cause mortality (ICD-10 codes A00 to Z99) and three specific causes of mortality: suicide (ICD-10 codes X60 to X84), cardiovascular disease (ICD-10 codes I00 to I99), and neoplasms (ICD-10 codes C00 to D49).

Antipsychotic usage levels were determined based on prescription records from the observation period. Prescription drugs were classified according to the Anatomical Therapeutic Chemical coding system, under which antipsychotics are coded as N05A; antidepressants are coded as N06AA, N06AB, N06AG, or N06AX; and benzodiazepines are coded as N03AE, N05BA, or N05CD. The antipsychotic drugs investigated in this study included amisulpride, aripiprazole, chlorpromazine, clozapine, haloperidol, levomepromazine, olanzapine, paliperidone, perphenazine, pimozide, quetiapine, risperidone, sulpiride, ziprasidone, and zotepine. The prescribed medication doses were estimated based on defined daily doses (DDDs), and cumulative antipsychotic doses were calculated by multiplying the prescribed medication dose by the number of prescription days and dividing by the DDD. If a participant was prescribed with more than one antipsychotic medication, all antipsychotic medication that the participants were prescribed with was considered when calculating the cumulative DDD. For instance, if a participant has been prescribed with 100 mg of Olanzapine (DDD_{Olanzapine} = 10 mg, cumulative DDD_{Olanzapine} = 100 mg/10 mg = 10DDD) and 6,000 mg of Clozapine (DDD_{Clozapine} = 300 mg, cumulative DDD_{Clozapine} = 6,000 mg/300 mg = 20DDD) during the follow up period, this participant’s cumulative DDD (cDDD) would be 30 DDD. The selected individuals were categorized into four cDDD groups: 1) non-use, defined as no antipsychotic usage during the observation period; 2) low-dose, defined as having a nonzero daily cDDD under 0.5; 3) moderate-dose, defined as having a daily cDDD of 0.5 to 1.5; and 4) high-dose, defined as having a daily cDDD greater than 1.5. This categorization scheme was used in a previous study [15].

The selected individuals were also categorized into 5-year age groups (age of diagnosis), and the Charlson Comorbidity Index (CCI) [17] was calculated for each individual. Under the CCI system, certain physical diseases (e.g., diabetes, tumor, etc.) have their own weight based on their severity. A score of 0 indicates that an individual does not have a comorbid disease, and higher CCI scores indicate that the patient has multiple comorbid diseases or a severe disease.

This study was approved by the Institutional Review Board of the National Center for Mental Health (116271-2021-09).

Statistical Analysis

To quantify the associations between antipsychotic cDDD groups and mortality rates, we used Cox regression analysis to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). The no-use condition consistently
**Table 1. Characteristics of the patient sample**

| Characteristic          | Number (%)          |
|-------------------------|---------------------|
| Age (yr)                |                     |
| 0−19                    | 432 (5.60)          |
| 20−29                   | 1,313 (17.03)       |
| 30−39                   | 1,711 (22.19)       |
| 40−49                   | 1,806 (23.42)       |
| 50−59                   | 1,080 (14.00)       |
| 60−69                   | 699 (9.06)          |
| ≥70                     | 671 (8.70)          |
| Sex                     |                     |
| Male                    | 3,807 (49.36)       |
| Female                  | 3,905 (50.64)       |
| Charlson Comorbidity Index |           |
| 0                       | 2,057 (26.67)       |
| 1                       | 2,050 (26.58)       |
| 2                       | 1,435 (18.61)       |
| ≥3                      | 2,170 (28.14)       |
| Antipsychotic exposure |                     |
| No use                  | 657 (8.52)          |
| Low use                 | 2,316 (30.03)       |
| Moderate use            | 3,201 (41.51)       |
| High use                | 1,538 (19.94)       |

**RESULTS**

The descriptive characteristics of the included individuals are presented in Table 1. The adjusted hazard ratios for all-cause and cause-specific mortality according to different antipsychotic exposure levels are listed in Table 2.

---

**Table 2. Causes of mortality and association with cumulative antipsychotic doses**

| Cause of mortality | No use (n = 657) | Low dose (n = 2,316) | Moderate dose (n = 3,201) | High dose (n = 1,538) | Use (combined) (n = 7,055) |
|--------------------|-----------------|----------------------|---------------------------|-----------------------|----------------------------|
| Deaths (n)         |                 |                      |                           |                       |                            |
|                   | 76              | 345                  |                           |                       |                            |
|                    | (0.96−1.57)     | (0.82−1.35)          |                           |                       |                            |
| All-cause          | 14              | 88                   |                           |                       |                            |
|                    | (0.98−3.02)     | (0.76−2.38)          |                           |                       |                            |
| Cardiovascular     | 12              | 38                   |                           |                       |                            |
| disease            | (0.45−1.65)     | (0.46−1.73)          |                           |                       |                            |
| Suicide            | 6               | 48                   |                           |                       |                            |
|                    | (0.91−4.94)     | (0.66−3.61)          |                           |                       |                            |
| Neoplasms          |                 |                      |                           |                       |                            |
|                    | (0.48−2.66)     | (0.81−4.57)          |                           |                       |                            |

The antipsychotic no-use group was used as a reference group for all HR calculations. HR, hazard ratio; aHR, HR adjusted for sex, age group, use of medications (i.e., antidepressants, benzodiazepines), and CCI; CCI, Charlson Comorbidity Index; CI, confidence interval.
risk of all-cause mortality (CHR = 0.71, 95% CI = 0.55–0.91). However, these associations disappeared after controlling for the covariates.

**DISCUSSION**

In this population-based cohort study, we investigated the effect of cumulative antipsychotic usage on all-cause and cause-specific mortality in patients with schizophrenia. After controlling for covariates, there was no significant association between antipsychotic usage at any dosage level and all-cause or cause-specific mortality in patients with schizophrenia.

Previous studies suggest that the use of clozapine [18,19] or long-acting injection antipsychotic drugs [20,21] lowers the mortality of those with schizophrenia. However, to date, only a few studies have examined the effect of cumulative antipsychotic usage on mortality in patients with schizophrenia and more research needs to be done to achieve consensus on the cumulative effect of antipsychotic use in schizophrenia mortality. These studies generally reported that antipsychotic usage lowered mortality risks in patients with schizophrenia, although dose-specific effects varied between studies. Two studies from Sweden [15] and Finland [18] found that moderate and high doses of antipsychotics were associated with reduced overall mortality for patients with schizophrenia. Another study from Sweden [16] found that low and moderate antipsychotic doses were associated with reduced mortality risks for patients with schizophrenia. Taipale et al. [18] suggested that antipsychotic usage reduces mortality by alleviating the symptoms of schizophrenia. Moreover, antipsychotic usage lowers cardiovascular mortality by reducing unhealthy behaviors (e.g., smoking and alcohol abuse) and stress [22-24]. Our findings also imply that excess mortality in schizophrenia may be attributable to factors other than antipsychotic treatment, which is in line with a previous study’s findings [16]. It is generally believed that excess mortality in patients with schizophrenia is largely attributable to unhealthy lifestyle factors, such as smoking, alcohol abuse, poor diet, and lack of exercise [25]. However, the factors associated with mortality in patients with schizophrenia remain unclear. Future studies are needed to identify these various factors.

This study had several limitations. First, we conducted a retrospective cohort study utilizing a national registry data. Therefore, there were limited information that was retrievable (e.g., the severity of schizophrenia could not be measured), and the presence or absence of each disease was classified based solely on ICD-10 codes. Second, because we only had access to data concerning physician-issued prescriptions, we could not determine the degree of adherence to antipsychotic therapy. Last but not least, the NHIS-NSC is comprised of 2% of the entire population in Korea and schizophrenia is a mental disorder with a relatively low prevalence rate. Therefore, future studies need to be conducted while utilizing the entire population in Korea to confirm the results found in this study.

The main strength of our study is that it used a nationally representative sample.

In conclusion, our results indicate that there is no significant association between antipsychotic usage at any dosage level and all-cause or cause-specific mortality in patients with schizophrenia. This implies that the excess mortality of patients with schizophrenia is attributable to factors other than antipsychotic use.

**Funding**

This work was supported by a clinical research grant (no. 2021-03) from the National Center for Mental Health, Republic of Korea.

**Conflicts of Interest**

No potential conflict of interest relevant to this article was reported.

**Author Contributions**

Conceptualization: Subin Park, Gyurin Kim. Methodology: Minkyung Jo. Statistical analysis: Min Geu Lee. Reference review: Gyurin Kim, Soo Jung Rim, Se Jin Park. Writing—original draft: Gyurin Kim, Soo Jung Rim, Se Jin Park, Min Geu Lee. Writing—review and editing: Subin Park, Se Jin Park, Soo Jung Rim. Approval of final manuscript: all authors.

**ORCID**

Gyurin Kim https://orcid.org/0000-0003-4486-695X
Soo Jung Rim https://orcid.org/0000-0003-4938-4116
Minkyung Jo https://orcid.org/0000-0002-4208-0024
Min Geu Lee https://orcid.org/0000-0003-2916-7421
Se Jin Park https://orcid.org/0000-0001-5561-2141
Subin Park https://orcid.org/0000-0002-4623-9899
REFERENCES

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. Arlington:American Psychiatric Association;2013.

2. Simeone JC, Ward AJ, Rotella P, Collins J, Windisch R. An evaluation of variation in published estimates of schizophrenia prevalence from 1990 – 2013: a systematic literature review. BMC Psychiatry. 2015;15:193.

3. Chong HY, Teoh SL, Wu DB, Kotirum S, Chiou CF, Chaiyakunapruk N. Global economic burden of schizophrenia: a systematic review. Neuropsychiatr Dis Treat 2016;12:357-373.

4. He H, Liu Q, Li N, Guo L, Gao F, Bai L, et al. Trends in the incidence and DALYs of schizophrenia at the global, regional and national levels: results from the Global Burden of Disease Study 2017. Epidemiol Psychiatr Sci 2020;29:e91.

5. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Möller HJ. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry. 2009;24:412-424.

6. Olsson M, Gerhard T, Huang C, Crystal S, Stroup TS. Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry 2015;72:1172-1181.

7. Ko YS, Tsai HC, Chi MH, Su CC, Lee IH, Chen PS, et al. Higher mortality and years of potential life lost of suicide in patients with schizophrenia. Psychiatry Res 2018;270:531-537.

8. Galletly CA. Premature death in schizophrenia: bridging the gap. Lancet Psychiatry 2017;4:263-265.

9. Weinmann S, Read J, Aderhold V. Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophr Res 2009;113:1-11.

10. Crump C, Winklesby MA, Sundquist K, Sundquist J. Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. Am J Psychiatry 2013;170:324-333.

11. Cullen BA, McGinty EE, Zhang Y, Dosreis SC, Steinwachs DM, Guallar E, et al. Guideline-concordant antipsychotic use and mortality in schizophrenia. Schizophr Bull 2013;39:1159-1168.

12. Baandrup L, Gasse C, Jensen VD, Glenthoj BY, Nordentoft M, Lublin H, et al. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. J Clin Psychiatry 2010;71:103-108.

13. Tiilinen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 2011;168:603-609. Erratum in: Am J Psychiatry 2012;169:223.

14. Tiilinen J, Lönneqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009;374:620-627.

15. Tiilinen J, Mittendorfer-Rutz E, Torniainen M, Alexanderson K, Tanskanen A. Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study. Am J Psychiatry 2016;173:600-606.

16. Torniainen M, Mittendorfer-Rutz E, Tanskanen A, Björkenstam C, Suvisaari J, Alexanderson K, et al. Antipsychotic treatment and mortality in schizophrenia. Schizophrenia Bull 2015;41:656-663. Erratum in: Schizophrenia Bull 2016;42:528.

17. Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol 2004;57:1288-1294.

18. Taipale H, Tanskanen A, Mehtälä J, Vattulainen P, Cornell CU, Tiilinen J. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry 2020;19:61-68.

19. Vermeulen JM, van Rooijen G, van de Kerkhof MPJ, Sutherland AL, Cornell CU, de Haan L. Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1-12.5 years. Schizophrenia Bull 2019;45:315-329.

20. Taipale H, Mittendorfer-Rutz E, Alexanderson K, Majak M, Mehtälä J, Hoti F, et al. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. Schizophr Res 2018;197:274-280.

21. Huang CY, Fang SC, Shao YJ. Comparison of long-acting injectable antipsychotics with oral antipsychotics and suicide and all-cause mortality in patients with newly diagnosed schizophrenia. JAMA Netw Open 2021;4:e218810. Erratum in: JAMA Netw Open 2022;5:e2210829.

22. Lahti M, Tiilinen J, Wildgust H, Beary M, Hodgson R, Kajantie E, et al. Cardiovascular morbidity, mortality and pharmacotherapy in patients with schizophrenia. Psychol Med 2012;42:2275-2285.

23. Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in schizophrenia. Annu Rev Clin Psychol 2014;10:425-448.

24. Oh J, Nam H, Park S, Chae JH, Kim TS. Decreased cardiovascular death in schizophrenia patients treated with antipsychotics: a Korean national cohort study. Schizophrenia Res 2021;228:417-424.

25. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000;177:212-217.